{"id":"NCT00650104","sponsor":"GlaxoSmithKline","briefTitle":"Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164","officialTitle":"101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-05","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-04-01","resultsPosted":"2010-04-21","lastUpdate":"2013-05-06"},"enrollment":76,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Ropinirole XL (formerly CR)","otherNames":[]}],"arms":[{"label":"Active","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.","primaryOutcome":{"measure":"Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)","timeFrame":"Screening; Week 4; Months 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, and 78","effectByArm":[{"arm":"Ropinirole XL","deltaMin":9.4,"sd":5.14}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["21244307"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":83},"commonTop":["Nausea","Dizziness","Oedema peripheral","Back pain","Headache"]}}